Who is sponsoring NCT05209802?

NCT05209802 is sponsored by Oslo Metropolitan University.

What drugs are being tested in NCT05209802?

Interventions in NCT05209802: Group A: High intensity exercise training, Group B: moderate intensity exercise training.

What condition does NCT05209802 study?

NCT05209802 studies Rheumatic Diseases.

Is NCT05209802 still recruiting?

NCT05209802 is currently completed. Last updated 7 February 2025.

Last reviewed 2025-02-07 · How we verify

NCT05209802: AquaHigh

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

High-intensity Aquatic Exercise for Adults with Rheumatic Diseases

Completed NA Last updated 7 February 2025

What this trial tests

NA trial testing Group A: High intensity exercise training in Rheumatic Diseases in 84 participants. Completed in 12 May 2023.

Timeline

1 February 2022

Primary endpoint
22 December 2022

12 May 2023

Quick facts

Lead sponsor	Oslo Metropolitan University
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	double
Primary purpose	treatment
Enrollment	84
Start date	1 February 2022
Primary completion	22 December 2022
Estimated completion	12 May 2023
Sites	1 location across Norway

Drugs / interventions tested

Group A: High intensity exercise training
Group B: moderate intensity exercise training

Conditions studied

Rheumatic Diseases — all drugs for Rheumatic Diseases →

Sponsor

Oslo Metropolitan University

Who can join

18 and older, any sex, with Rheumatic Diseases. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study is to compare aquatic high intensity interval training with moderate intensity exercise training on exercise capacity in a population with rheumatic diseases.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Effects of aquatic high-intensity interval training on aerobic capacity in adults with rheumatic and musculoskeletal diseases: the AquaHigh randomised controlled trial.
Bunæs-Næss H, Heywood SE, Kvæl LAH, Heiberg KE, et al · · 2025 · cited 1× · PMID 40132852 · DOI 10.1136/bmjopen-2024-090612
Effects of aquatic high-intensity interval training on patient-reported outcome measures and quality-adjusted life-years in adults with rheumatic and musculoskeletal diseases: a secondary analysis of the AquaHigh randomised controlled trial.
Bunæs-Næss H, Nilsson BB, Kvæl LAH, Heywood SE, et al · · 2025 · PMID 41238358 · DOI 10.1136/bmjopen-2025-102841

Verify or expand the search:

Other recruiting trials for Rheumatic Diseases

Currently open trials in the same condition.

NCT07490041 — Exploratory Clinical Study on the Safety and Efficacy of Anti- CD19/BCMA CAR-NK Cell Injection for the Treatment of Refr · EARLY_PHASE1 · recruiting
NCT07350395 — Exploring and Measuring the Impact of Steroids in Children and Young People · recruiting
NCT07278609 — The RheumSafer Study: Improving Medication Appropriateness in People With Rheumatic Conditions · recruiting
NCT07148414 — A Study of SPY072 in Rheumatic Disease · Phase 2 · recruiting
NCT06400628 — Effectiveness of Chronic Self-management Education on Behavioral and Clinical Outcomes · NA · recruiting

Other Oslo Metropolitan University trials

Trials by the same sponsor.

NCT06578260 — Support Groups - a Model for Social Inclusion and Reduction of Bullying in School · NA · recruiting
NCT05784324 — COMPRESSED - A Longitudinal Study of Compressed Work Schedules Within the Health, Care and Welfare Services · not yet recruiting
NCT05895604 — The Mother in Norway Study · NA · recruiting
NCT06117098 — Mobile App for Risk Reduction of Type 2 Diabetes · NA · unknown
NCT05697120 — Long-term Effects of Individualized Follow-up With an App for One Year · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05209802 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Oslo Metropolitan University
Last refreshed: 7 February 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05209802.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing